14 august 2020

China Sinopharm's potential COVID-19 vaccine triggers antibodies in clinical trials: journal


BEIJING (Reuters) - A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said. FILE PHOTO: The company logo of Sinopharm Group Co Ltd is displayed at a news conference on the company's annual results in Hong Kong, China March 29, 2016. REUTERS/Bobby Yip/File Photo The candidate has already moved into a late-stage trial, one of a handful [...]